NCT06847035

Efficacy Study of Oral Collagen Peptide on Skin Condition Improvement

Efficacy Study of Oral Collagen Peptide on Skin Conditions

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Shanghai Meifute Biotechnology Co., Ltd · Industry
• Sex: Female
• Age: 35 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

To assess if oral intake of collagen peptide can improve skin conditions such as skin thickness, density and firmness.

Detailed description

This is an one site, randomized, double-blind controlled clinical trial to assess the oral supplement of LISAVEI collagen peptide solid beverage on skin ageing improvement. Study product with collagen peptide and placebo product without collagen were randomly assigned to 90 eligible participants enrolled according to the inclusion and exclusion criteria. They took the assigned product once daily dissolved in 100 ml warm water for 12 weeks with 4-week regression phase(without intake of the test products), and visit the study site in Shanghai for four times(before starting the treatment, after 8 and 12 weeks, and 4 weeks after the last intake). Skin measurements including skin firmness, skin density, skin hydration and skin barrier were carried out at each visit with professional equipment and imaging system. Data were analyzed to validate if the administration of the test collagen peptide solid beverage will improve skin aging parameters such as firmness, thickness, density, hydration and skin barrier compared to placebo. The lasting effect was also observed by comparing between the two groups after 4-week regression time.

Conditions

• Skin Aging

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Active Comparator	LISAVEI collagen peptide solid beverage ( contain 5 g collagen peptide)，once daily for 12 weeks
DIETARY_SUPPLEMENT	Placebo Comparator	placebo solid beverage (Maltodextrin with edible flavor)，once daily for 12 weeks

Timeline

• Start date: 2024-07-25
• Primary completion: 2024-11-19
• Completion: 2024-11-19
• First posted: 2025-02-26
• Last updated: 2025-02-28

Locations

1 site across 1 country: China